Early Haematological Response and Short-Term Safety of Frontline Imatinib in Adults with Chronic Myeloid Leukaemia: A Retrospective Study in a Resource-Limited Setting
Sara S. Abdelrahim, Mohammed H. Alnazeer, Mawahib A. Mustafa, Safa A. Abdalla, Elkhanssa Abdelhameed Ahmed Elhag, Kannan O. Ahmed, Yasir S. Kheir, Elmoiz Babekir & Bashir A. Yousef · Journal of Advances in Medical and Pharmaceutical Sciences · 2026
Background: Imatinib mesylate is a tyrosine kinase inhibitor that has transformed the treatment of chronic myeloid leukaemia. However, information on its real-world use among sub-Saharan African populations remains limited. Aims: This study evaluated early haematological response...
Open access
Research Article
10.9734/jamps/2026/v28i8879